A nomogram for predicting overall survival in patients with muscle-invasive bladder cancer undergoing radical cystectomy: a retrospective cohort study
Background and aimsRadical cystectomy (RC) remains the standard treatment for localized and regionally muscle-invasive bladder cancer (MIBC). However, only half of patients with MIBC survive more than 5 years after RC. We explored the factors associated with overall survival (OS) and constructed a p...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-06-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1597107/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Background and aimsRadical cystectomy (RC) remains the standard treatment for localized and regionally muscle-invasive bladder cancer (MIBC). However, only half of patients with MIBC survive more than 5 years after RC. We explored the factors associated with overall survival (OS) and constructed a prognostic nomogram for predicting 1-, 3-, and 5-year OS after RC.MethodsThe data were sourced from the Surveillance, Epidemiology, and End Results (SEER) database and Peking University First Hospital (PKUFH). Univariate and multivariate Cox regression analyses were performed using the minimum value of the Akaike information criterion to select independent prognostic factors that significantly contributed to patient survival. A prognostic nomogram was designed to predict 1-, 3-, and 5-year OS.ResultsAmong the 16,949 patients with MIBC undergoing surgery, 31.15% survived for more than 5 years. The nomogram we created demonstrated satisfactory discriminative ability to predict the survival of MIBC patients with RC, with area under curve (AUC) of 0.939, 0.880 and 0.852 for 1-, 3- and 5-year OS in the testing set. Moreover, the nomogram still exhibited good performance in an externally independent dataset (1-year: AUC=0.970; 3-year: AUC=0.847; 5-year: AUC=0.790). Furthermore, decision curve analyses showed a modest net benefit for the use of the MIBC nomogram in the current cohort compared to the use of American Joint Committee on Cancer staging alone.ConclusionsA prognostic nomogram was developed and validated to help clinicians evaluate the prognosis of postoperative MIBC patients. The future integration of additional data will likely improve model performance and accuracy for personalized prognostics. |
|---|---|
| ISSN: | 2234-943X |